Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361939 | 0.93 | STING1 (0.31) | STING1 | |
| SCHEMBL25495878 | 0.93 | STING1 (0.31) | STING1 | |
| SCHEMBL29138749 | 0.93 | STING1 (0.31) | STING1 | |
| SCHEMBL14190503 | 0.89 | — | — | |
| SCHEMBL16329787 | 0.89 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30180784 | 0.86 | HDAC3 (0.31) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL14407229 | 0.84 | HDAC3 (0.33) | STING1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16329775 | 0.84 | TLR2 (0.37) | HDAC3HDAC1EPHX2 | |
| SCHEMBL26079446 | 0.84 | STING1 (0.31) | STING1 | |
| SCHEMBL14343056 | 0.82 | HDAC3 (0.33) | STING1HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144883-A1 | ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF | XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD. (CN) | 2026-05-28 | — | — | US | disclosed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731261-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731257-A1 | CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-4719478-A1 | IMPROVED TREATMENT REGIMENS FOR THERAPEUTIC EFFECTOR COMPONENTS THAT ACT VIA AN INTRACELLULAR MOLECULAR TARGET | Sapreme Technologies B.V. (NL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-19 | — | — | US | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043900-A1 | DRUG TRANSFER BASED ON COENZYME A AND ACYL CARRIER PROTEIN | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009013359-A2 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS | FRAUNHOFER GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. (DE) | 2009-01-29 | — | — | WO | disclosed |
| US-20080274915-A1 | Solid Substrate Comprising Array of Dendrons and Methods for Using the Same | PARK JOON WON | 2008-11-06 | — | — | US | disclosed |
| US-20080274915-A1 | Solid Substrate Comprising Array of Dendrons and Methods for Using the Same | PARK JOON WON | 2008-11-06 | — | — | US | disclosed |
| US-20080274915-A1 | Solid Substrate Comprising Array of Dendrons and Methods for Using the Same | PARK JOON WON | 2008-11-06 | — | — | US | disclosed |
| WO-2007135483-A2 | BIOMOLECULE INTERACTION USING ATOMIC FORCE MICROSCOPE | POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070128623-A1 | Cantilevers with fixed end and free end modified by dendron | POSTECH FOUNDATION (KR) | 2007-06-07 | — | — | US | disclosed |
| US-20070128623-A1 | Cantilevers with fixed end and free end modified by dendron | POSTECH FOUNDATION (KR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076989-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | NSUN2, TLR9, MSR1 | STING1 30/4885HDAC3 1578/4885HDAC1 2144/4885 |
| US-20260144883-A1 | ANTI-TROP2/EGFR ANTIBODIES AND USES THEREOF | ERBB2, EGFR, ERBB3 | STING1 487/4885HDAC3 4640/4885HDAC1 4730/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | STING1 1109/4885HDAC3 2362/4885HDAC1 2357/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | STING1 1412/4885HDAC3 4010/4885HDAC1 4212/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | STING1 1832/4885HDAC3 4594/4885HDAC1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.